Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1594–1602. doi: 10.1038/sj.bjc.6690254

The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines

S Majumdar 1, E P Diamandis 1
PMCID: PMC2362704  PMID: 10188912

Abstract

KLK3 or prostate specific antigen (PSA) is a serine protease, which is an established tumour marker of prostatic adenocarcinoma. PSA is now used widely for the diagnosis and monitoring of patients with prostate cancer. Recent studies have demonstrated that about 70% of breast cancers produce PSA. In this study, we examined the molecular mechanism underlying the expression of the PSA gene in breast cancer and breast cancer cell lines. We analysed nine breast tumours categorized on the basis of high- or low-PSA expression in tumour cytosols and four breast cancer cell lines. To determine abnormalities associated with PSA expression in breast tumours, genomic DNA was extracted and all five exons of the PSA gene were polymerase chain reaction (PCR) amplified and sequenced on both strands. PCR amplification was also performed for the promoter and enhancer elements of the PSA gene. No mutations were observed in the coding portion of the gene. A polymorphism was observed in exon 2 from three breast tumours. However, sequencing of the promoter and the enhancer elements of the PSA gene reveals several point mutations. Within a 5.8-kb promoter/enhancer region of the PSA gene, we detected 16 different mutational hotspots (appearing more than once in the nine tumours). Among these hotspots, two appeared in seven out of nine tumours. Most importantly, the androgen response element (ARE I) in the proximal promoter was found mutated in four tumours and in the breast carcinoma cell line MCF-7. Mutations associated with the ARE I have been shown previously to result in an 80% decrease in PSA gene expression. The mutations in the core enhancer and promoter region probably contribute to the aberrant expression of the PSA gene in breast tumours, possibly by altering the regulation of the gene by steroid hormones. © 1999 Cancer Research Campaign

Keywords: prostate specific antigen gene, mutations, promoter, enhancer, breast cancer

Full Text

The Full Text of this article is available as a PDF (235.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cairns C., Gustafsson J. A., Carlstedt-Duke J. Identification of protein contact sites within the glucocorticoid/progestin response element. Mol Endocrinol. 1991 Apr;5(4):598–604. doi: 10.1210/mend-5-4-598. [DOI] [PubMed] [Google Scholar]
  2. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  3. Cleutjens K. B., van der Korput H. A., van Eekelen C. C., van Rooij H. C., Faber P. W., Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997 Feb;11(2):148–161. doi: 10.1210/mend.11.2.9883. [DOI] [PubMed] [Google Scholar]
  4. Digby M., Zhang X. Y., Richards R. I. Human prostate specific antigen (PSA) gene: structure and linkage to the kallikrein-like gene, hGK-1. Nucleic Acids Res. 1989 Mar 11;17(5):2137–2137. doi: 10.1093/nar/17.5.2137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Graff J. R., Herman J. G., Lapidus R. G., Chopra H., Xu R., Jarrard D. F., Isaacs W. B., Pitha P. M., Davidson N. E., Baylin S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995 Nov 15;55(22):5195–5199. [PubMed] [Google Scholar]
  6. Henttu P., Liao S. S., Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 1992 Feb;130(2):766–772. doi: 10.1210/endo.130.2.1370795. [DOI] [PubMed] [Google Scholar]
  7. Hoffman B. R., Yu H., Diamandis E. P. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clin Chem. 1996 Apr;42(4):536–544. [PubMed] [Google Scholar]
  8. Levesque M., Hu H., D'Costa M., Diamandis E. P. Prostate-specific antigen expression by various tumors. J Clin Lab Anal. 1995;9(2):123–128. doi: 10.1002/jcla.1860090209. [DOI] [PubMed] [Google Scholar]
  9. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985 Nov;76(5):1899–1903. doi: 10.1172/JCI112185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun. 1989 Jun 30;161(3):1151–1159. doi: 10.1016/0006-291x(89)91362-4. [DOI] [PubMed] [Google Scholar]
  11. MacDonald R. J., Margolius H. S., Erdös E. G. Molecular biology of tissue kallikrein. Biochem J. 1988 Jul 15;253(2):313–321. doi: 10.1042/bj2530313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McCormack R. T., Rittenhouse H. G., Finlay J. A., Sokoloff R. L., Wang T. J., Wolfert R. L., Lilja H., Oesterling J. E. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995 May;45(5):729–744. doi: 10.1016/s0090-4295(99)80076-4. [DOI] [PubMed] [Google Scholar]
  13. Ottaviano Y. L., Issa J. P., Parl F. F., Smith H. S., Baylin S. B., Davidson N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994 May 15;54(10):2552–2555. [PubMed] [Google Scholar]
  14. Pisani P., Parkin D. M., Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993 Dec 2;55(6):891–903. doi: 10.1002/ijc.2910550604. [DOI] [PubMed] [Google Scholar]
  15. Riegman P. H., Vlietstra R. J., Suurmeijer L., Cleutjens C. B., Trapman J. Characterization of the human kallikrein locus. Genomics. 1992 Sep;14(1):6–11. doi: 10.1016/s0888-7543(05)80275-7. [DOI] [PubMed] [Google Scholar]
  16. Riegman P. H., Vlietstra R. J., van der Korput H. A., Romijn J. C., Trapman J. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol. 1991 Apr;76(1-3):181–190. doi: 10.1016/0303-7207(91)90272-t. [DOI] [PubMed] [Google Scholar]
  17. Riegman P. H., Vlietstra R. J., van der Korput J. A., Romijn J. C., Trapman J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun. 1989 Feb 28;159(1):95–102. doi: 10.1016/0006-291x(89)92409-1. [DOI] [PubMed] [Google Scholar]
  18. Sauter E. R., Daly M., Linahan K., Ehya H., Engstrom P. F., Bonney G., Ross E. A., Yu H., Diamandis E. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967–970. [PubMed] [Google Scholar]
  19. Schedlich L. J., Bennetts B. H., Morris B. J. Primary structure of a human glandular kallikrein gene. DNA. 1987 Oct;6(5):429–437. doi: 10.1089/dna.1987.6.429. [DOI] [PubMed] [Google Scholar]
  20. Schulz P., Stucka R., Feldmann H., Combriato G., Klobeck H. G., Fittler F. Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leader sequence. Nucleic Acids Res. 1988 Jul 11;16(13):6226–6226. doi: 10.1093/nar/16.13.6226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schuur E. R., Henderson G. A., Kmetec L. A., Miller J. D., Lamparski H. G., Henderson D. R. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 1996 Mar 22;271(12):7043–7051. doi: 10.1074/jbc.271.12.7043. [DOI] [PubMed] [Google Scholar]
  22. Smith M. R., Biggar S., Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res. 1995 Jun 15;55(12):2640–2644. [PubMed] [Google Scholar]
  23. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  24. Truss M., Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev. 1993 Aug;14(4):459–479. doi: 10.1210/edrv-14-4-459. [DOI] [PubMed] [Google Scholar]
  25. Watt K. W., Lee P. J., M'Timkulu T., Chan W. P., Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A. 1986 May;83(10):3166–3170. doi: 10.1073/pnas.83.10.3166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416–7419. doi: 10.1073/pnas.92.16.7416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Young C. Y., Andrews P. E., Montgomery B. T., Tindall D. J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992 Jan 28;31(3):818–824. doi: 10.1021/bi00118a026. [DOI] [PubMed] [Google Scholar]
  28. Yu H., Diamandis E. P., Levesque M., Asa S. L., Monne M., Croce C. M. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res. 1995 Apr 15;55(8):1603–1606. [PubMed] [Google Scholar]
  29. Yu H., Diamandis E. P., Zarghami N., Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat. 1994;32(3):291–300. doi: 10.1007/BF00666006. [DOI] [PubMed] [Google Scholar]
  30. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]
  31. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. von der Ahe D., Janich S., Scheidereit C., Renkawitz R., Schütz G., Beato M. Glucocorticoid and progesterone receptors bind to the same sites in two hormonally regulated promoters. Nature. 1985 Feb 21;313(6004):706–709. doi: 10.1038/313706a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES